Get the Stockscreener App
14.53
0.00%
0.00
After Hours:
14.82
0.29
+2.00%
Adaptive Biotechnologies Corp stock is traded at $14.53, with a volume of 949.01K.
It is up +0.00% in the last 24 hours and up +10.33% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
See More
Previous Close:
$14.53
Open:
$14.53
24h Volume:
949.01K
Relative Volume:
0.47
Market Cap:
$2.24B
Revenue:
$276.98M
Net Income/Loss:
$-59.46M
P/E Ratio:
-36.44
EPS:
-0.3987
Net Cash Flow:
$-48.95M
1W Performance:
-2.09%
1M Performance:
+10.33%
6M Performance:
-15.08%
1Y Performance:
+87.73%
1-Day Range:
$14.44
$14.86
1-Week Range:
$12.36
$14.86
52-Week Range:
$6.7747
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
14.53 | 2.24B | 276.98M | -59.46M | -48.95M | -0.3987 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Adaptive Biotechnologies schedules May 5 webcast for Q1 2026 results - Stock Titan
Adaptive Biotechnologies (ADPT) moves 5.8% higher: Will this strength last? - MSN
Adaptive Biotechnologies (ADPT) president Rubinstein sells $758k in stock By Investing.com - Investing.com India
Adaptive Biotechnologies (ADPT) president Rubinstein sells $758k in stock - Investing.com
Adaptive Biotechnologies (NASDAQ: ADPT) COO sells shares under 10b5-1 plan - Stock Titan
Insider Sell: Harlan Robins Sells Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus
Adaptive Biotechnologies (ADPT) chief people officer sells $340k in stock By Investing.com - Investing.com India
Robins, Adaptive Biotechnologies CSO, sells $148,500 in stock By Investing.com - Investing.com Canada
Adaptive Biotechnologies (ADPT) chief people officer sells $340k in stock - Investing.com
Robins, Adaptive Biotechnologies CSO, sells $148,500 in stock - Investing.com
Adaptive Biotechnologies (ADPT) officer sells shares after option exercise - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) CSO sells 10,000 shares under 10b5-1 plan - Stock Titan
Adaptive Biotechnologies Corp. Opens with a 9.41% Gain, Outperforming S&P 500 - Markets Mojo
Adaptive Biotechnologies Hits Day High with 8.24% Surge in Stock Price - Markets Mojo
Insider Sell: Chad Robins Sells 120,595 Shares of Adaptive Biote - GuruFocus
Adaptive Biotechnologies president Rubinstein sells $990k in ADPT stock By Investing.com - Investing.com India
Adaptive Biotechnologies CEO Robins sells $1.76m in ADPT stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies president Rubinstein sells $990k in ADPT stock - Investing.com
[Form 4] Adaptive Biotechnologies Corp Insider Trading Activity - Stock Titan
ADPT COO Rubinstein sells shares, exercises options under 10b5-1 plan - Stock Titan
Affiliate resale notice for ADPT (NASDAQ: ADPT) — 10,000 shares listed - Stock Titan
ADPT (ADPT) insider Chad M. Robins sells blocks totaling six‑figure proceeds - Stock Titan
ADPT (NASDAQ: ADPT) affiliate files Form 144 listing 22,564 shares for sale - Stock Titan
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On - The Motley Fool
Affiliate sales disclosed for Adaptive Biotechnologies (NASDAQ: ADPT) in Form 144 - Stock Titan
Adaptive Biotechnologies Hits Day Low of $12.02 Amid Price Pressure - Markets Mojo
A Look At Adaptive Biotechnologies (ADPT) Valuation After Q4 2025 Beat And New Pfizer Agreements - Yahoo Finance
ADPT Technical Analysis & Stock Price Forecast - Intellectia AI
Adaptive Biotechnologies CSO Robins sells $799k in ADPT stock - Investing.com
Adaptive Biotechnologies CSO Robins sells $392,329 in ADPT stock - Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 19,060 Shares - MarketBeat
Adaptive Biotechnologies president sells $553,693 in ADPT stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies president sells $553,693 in ADPT stock - Investing.com
Adaptive Biotechnologies (ADPT) COO exercises options and sells 38K shares - Stock Titan
ADPT PE Ratio & Valuation, Is ADPT Overvalued - Intellectia AI
ADPT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Adaptive Biotechnologies (ADPT) president sells $751k in stock By Investing.com - Investing.com India
Adaptive Biotechnologies (ADPT) president sells $751k in stock - Investing.com
Adaptive Biotech (NASDAQ: ADPT) COO sells 57,180 shares in 10b5-1 plan - Stock Titan
Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look - The Motley Fool
A Look At Adaptive Biotechnologies (ADPT) Valuation After Recent Share Price Weakness - simplywall.st
Adaptive Biotechnologies (NASDAQ:ADPT) Trading Down 6.7%Here's What Happened - MarketBeat
Adaptive Biotechnologies’ president Rubinstein sells $802k in ADPT stock By Investing.com - Investing.com India
Adaptive Biotechnologies (ADPT) COO sells shares under Rule 10b5-1 plan - Stock Titan
Adaptive Biotechnologies’ president Rubinstein sells $802k in ADPT stock - Investing.com
Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year - AOL.com
[SCHEDULE 13G/A] Adaptive Biotechnologies Corp Amended Passive Investment Disclosure - Stock Titan
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake - MSN
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):